Co-financed by:

Project Definition | SI I&DT | EXOLUNG: Umbilical Cord Blood derived exosomes for treatment of COVID-19 related Acute Respiratory Distress Syndrome (ARDS)

Project code | CENTRO-01-02B7-FEDER-070018

Main objective |EXOLUNG project aims to develop a new therapy for the treatment of acute respiratory distress syndrome using a technology based on exosomes derived from umbilical cord blood cells.

Execution Region |Centre

Target Entity| Exogenus Therapeutics, S.A.

Approval date |18th of August 2020

Starting date | 2nd October 2020

Ending date | 1st October 2021

Total eligible costs |493.165,66€

European Union Financial support FEDER | 486.912,37€


Exogenus Therapeutics has a proprietary active substance in development (Exo-101) which has anti-inflammatory and regenerative properties already tested and proven on skin, which also regulates the immune inflammatory response at a systemic level. In this project, we will evaluate if Exo-101 characteristics are able to control the aggravated inflammation of the lung as a result of SARS-CoV-2 infection. If proven, this effect will allow recovery of the lung function in COVID-19 patients, avoiding the use of medically assisted ventilation, and in some cases, death. We will use cellular and animal models that mimic the inflammatory context of COVID-19 related ARDS (Acute Respiratory Distress Syndrome), to evaluate if Exo-101 can prevent lung damage by blocking the inflammatory process leading to ARDS. If the results are positive, we will move towards the definition of the product development roadmap, aiming to use Exo-101 for the treatment of ARDS in COVID-19 patients, or any other pathology that causes ARDS. This roadmap will support us in raising funds for the next product development steps.